Blog
RSS FeedPosted by Michael Wonder on 31 May 2022
Schedule of Pharmaceutical Benefits - 1 June 2022
1 June 2022 - The June 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 May 2022
2022 Biosimilar Awareness Week: 30 May – 3 June
30 May 2022 - Marking a new dawn in medicine choice and affordability. ...
Posted by Michael Wonder on 07 Dec 2021
Biosimilar follitropin alfa on the PBS - information for health care professionals and patients
7 December 2021 - A biosimilar brand of follitropin alfa (Ovaleap) was listed on the PBS on 1 December 2021. ...
Posted by Michael Wonder on 19 Oct 2021
Strategies for generic/biosimilar market entry in Australia
19 October 2021 - After surviving the Great Patent Cliff of 2011–2016, the pharma/biopharma industry finds itself in the Second Great ...
Posted by Michael Wonder on 08 Oct 2021
Docs ‘use rubber stamp for drugs’
9 October 2021 - Pharmacists have raised the alarm over the influence of a US pharmaceutical corporation on Australian doctors ...
Posted by Michael Wonder on 02 Jul 2021
Bevacizumab on the PBS
2 July 2021 - Mvasi, a biosimilar brand of bevacizumab, was listed on the PBS from 1 June 2021, as ...
Posted by Michael Wonder on 21 May 2021
Biosimilar bevacizumab on the PBS - information for health professionals and patients
21 May 2021 - A biosimilar brand of bevacizumab (Mvasi) will be listed on the PBS on 1 June 2021. Information ...
Posted by Michael Wonder on 30 Mar 2021
Samsung Bioepis continues global market expansion with launch of Hadlima in Australia and Canada in partnership with Merck
29 March 2021 - Samsung Bioepis’ adalimumab is now available in three markets: Europe, Canada and Australia. ...
Posted by Michael Wonder on 14 Feb 2021
Biosimilars: is interchangeability the proof of the pudding?
15 February 2021 - While apparently non‐inferior to originator biologics, other factors need to be considered before switching ...
Posted by Michael Wonder on 10 Sep 2020
Biosimilar pegfilgrastim on the PBS - information for health professionals and patients
11 September 2020 - A biosimilar brand of pegfilgrastim (Pelgraz) was listed on the PBS on 1 August 2020. ...
Posted by Michael Wonder on 27 Jul 2020
Biosimilar insulin glargine on the PBS - information for health professionals and patients
27 July 2020 - Changes have been made from 1 July 2020 to the PBS listings for insulin glargine, as the ...
Posted by Michael Wonder on 14 Jul 2020
Biosimilar Awareness Week proves successful for Australia
13 July 2020 - The Generic and Biosimilar Medicines Association in Australia reported its 2020 Biosimilar Awareness Week was successful, with ...
Posted by Michael Wonder on 26 May 2020
New biosimilar trastuzumab on the PBS - information for health professionals and patients
26 May 2020 - A biosimilar brand of trastuzumab (Trazimera) was listed on the PBS on 1 May 2020. ...
Posted by Michael Wonder on 01 Feb 2020
Biosimilar rituximab on the PBS - information for health professionals and patients
1 February 2020 - On 1 February 2020 changes were made to the PBS listings for the biosimilar rituximab brand Truxima. ...
Posted by Michael Wonder on 02 Jan 2020
Biosimilar trastuzumab and rituximab on the PBS - information for health professionals and patients
2 January 2019 - New biosimilar brands of trastuzumab (Ontruzant) and rituximab (Truxima) have listed on the PBS on 1 January ...